The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Chemotherapy plus anti-EGFR treatment after progression for pMMR/MMS RAS/BRAF wild-type mCRC
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, describes an individualized patient data analysis of 5 randomized clinical trials evaluating chemotherapy plus anti-EGFR retreatment versus switched chemotherapy plus anti-VEGF treatment after progression in mismatch repair proficient/microsatellite stable (pMMR/MSS) RAS/BRAF wild-type metastatic colorectal cancer (mCRC). A good positive signal was seen for continued anti-EGFR therapy, however Dr O’Connor cautions that these results were not obtained from a comparative randomized clinical trial. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
